US pharmaceutical company Merck & Co is to price its new treatment for AIDS, Crixivan (indinavir) in European currency units uniformly across the European Union.
The company says that the move is aimed at ensuring that there is fair access to the drug for all, reports Reuters. The company is also breaking with the standard practice in the industry of setting different prices for drugs sold to individual countries.
The EU approved Merck's product on October 4, and Merck will charge 9.64 Ecus ($12.03) a day for the product leaving factories.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze